tbuckley/cabot-search huggingface dataset:
Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts is associated with loss of adhesion molecule and pro-invasive ECM species transcripts
Authors: Christopher Lipinski, Wendy McDonough, Jean Kloss, Brock Armstrong, Michael Berens, Joseph Loftus
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

3032 

Disease progression of high grade glioma involves a complex interplay between tumor cells and the peri-tumor microenvironment. Predilection of glioma cells to invade locally is problematic in that dispersing cells are less sensitive to radiotherapy and chemotherapeutics. Focal adhesion kinases (FAK and Pyk2) are important functional modifiers of glioma; Pyk2 exerts pro-migratory and FAK pro-proliferative influences in vitro . Selective targeting of Pyk2 may be a therapeutic strategy to control invasion. We now report on the transcriptional consequences of Pyk2 or FAK knockdown (lentiviral shRNA infection) and correlate selective elimination of these focal adhesion kinases with disease progression in an orthotopic xenograft model. Cohorts of 8 mice were orthotopically grafted with either SF767 wild type (WT), SF767 Pyk2 knockdown cells (Pyki), or SF767 FAK knockdown (FAKi) cells. The primary outcome measure was the time to morbidity (Kaplan-Meier analysis) with between-groups statistical comparisons calculated by log-rank tests with confidence intervals (bootstrap method). The median time to morbidity for WT mice was 19 days (95% CI= 18-25) compared to Pyki (37d [30-41], p <0.001), and FAKi (39d [39-41], p<0.001). Global gene expression analysis (Affymetrix U133A 2.0) comparing the profiles of WT cells with Pyki or FAKi cells yielded 19 transcripts that were either up- or down-regulated in both knockdown cells. Among the 8 down-regulated transcripts there were 3 pro-invasive matrix components (LPXN, LAMC2, and LAMA3), 1 ECM receptor (ITGA2), 1 cell adhesion receptor (CYR61), 1 protein tyrosine phosphatase-interacting protein (PPRIBP1), 1 Rho-GDP dissociation inhibitory protein (ARHGDIB), and 1 proliferation factor (TGFBI). Intriguingly, the GBM relevant phosphatase PTEN is substantially up-regulated in both Pyki and FAKi cells. In vitro functional studies confirmed a reduction in the adhesiveness of Pyki and FAKi cells to ECM relative to SF767 WT. In conclusion, extended in vivo survival of mice bearing Pyk2 or FAK knockdown glioma xenografts appears to involve, in part, reduced expression of molecules involved in matrix adhesion and pro-invasiveness. The findings support therapeutic targeting of glioma invasion signaling as a means to extend survival. (Supported by R01CA103956 and 1R01NS42262).
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Authors: Brian Hutton, Georgia Salanti, Deborah M. Caldwell, Anna Chaimani, Christopher H. Schmid, Chris Cameron, John P.A. Ioannidis, Sharon Straus, Kristian Thorlund, Jeroen P. Jansen, Cynthia Mulrow, Ferrán Catalá-López, Peter C. Gøtzsche, Kay Dickersin, Isabelle Boutron, Douglas G. Altman, David Moher
Journal: Annals of Internal Medicine (2015)

The PRISMA statement is a reporting guideline designed to improve the completeness of reporting of systematic reviews and meta-analyses. Authors have used this guideline worldwide to prepare their reviews for publication. In the past, these reports typically compared 2 treatment alternatives. With the evolution of systematic reviews that compare multiple treatments, some of them only indirectly, authors face novel challenges for conducting and reporting their reviews. This extension of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement was developed specifically to improve the reporting of systematic reviews incorporating network meta-analyses. A group of experts participated in a systematic review, Delphi survey, and face-to-face discussion and consensus meeting to establish new checklist items for this extension statement. Current PRISMA items were also clarified. A modified, 32-item PRISMA extension checklist was developed to address what the group considered to be immediately relevant to the reporting of network meta-analyses. This document presents the extension and provides examples of good reporting, as well as elaborations regarding the rationale for new checklist items and the modification of previously existing items from the PRISMA statement. It also highlights educational information related to key considerations in the practice of network meta-analysis. The target audience includes authors and readers of network meta-analyses, as well as journal editors and peer reviewers.
Standardization of Diabetics with Diet and Insulin
Authors: Joseph T. Beardwood
Journal: Annals of Internal Medicine (1933)

Article1 May 1933Standardization of Diabetics with Diet and InsulinJOSEPH T. BEARDWOOD JR., A.B., M.D., F.A.C.P.JOSEPH T. BEARDWOOD JR., A.B., M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-6-11-1407 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOne hesitates to use the term "standardization" in relation to the treatment of disease. We rightly should consider each patient as an individual and adapt our treatment accordingly.In the management of diabetes the term "standardization", however, is used to indicate two necessary steps in treatment. The first is the control of the disease, by which is meant the reduction of the blood sugar to normal levels, with or without insulin, with the patient on a maintenance diet. A maintenance diet may be defined as a diet containing a properly balanced proportion of carbohydrate, protein, and fat, and sufficient total...Reference1 BEARDWOODKELLY JTHT: Simplified diabetic management, 1931, J. B. Lippincott Co., Philadelphia, 67. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Philadelphia, Pennsylvania*Presented before the Main Line County Medical Society, Haverford, Pa., March 12, 1932. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1933Volume 6, Issue 11Page: 1407-1411KeywordsBlood sugarCarbohydratesDietFatsInsulinProteins ePublished: 1 December 2008 Issue Published: 1 May 1933 PDF downloadLoading ...
Case history: Lessons learned from the MGMT methylation experience
Authors: Manel Esteller
Journal: Clinical Cancer Research (2006)

PL-03   Promoter CpG island hypermethylation can be used as predictor of response to different treatments. The case for this needs to be made for each gene separately. The most compelling evidence is provided by the methylation-associated silencing of the DNA repair MGMT in human cancer. The MGMT protein (O6-methylguanine DNA methyltransferase) is directly responsible for repairing the addition of alkyl groups to the guanine (G) base of the DNA. This base is the preferred point of attack in the DNA of several alkylating chemotherapeutic drugs, such as BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea), ACNU (1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea), procarbazine, streptozotocin, or temozolamide. Thus, our reasoning was that tumors that had lost MGMT due to hypermethylation would be more sensitive to the action of these alkylating agents since their DNA lesions could not be repaired in the cancer cell and so this would lead to cell death. We gave proof of principle for this hypothesis and effectively MGMT promoter hypermethylation predicts a good response to chemotherapy, greater overall survival, and longer time to progression in glioma patients treated with BCNU(carmustine). This study has been followed up by other groups, who have obtained similar results. It is important to note that MGMT hypermethylation alone, without treatment with an alkylating agent, is not a good prognostic factor per se. In fact, it is a poor prognostic factor, probably due to the finding that patients with epigenetic silencing of MGMT accumulate more mutations, as demonstrated for p53 and K-ras in colorectal, brain  and lung  tumors. The potential of MGMT to predict the chemoresponse of human tumors to alkylating agents is not limited to BCNU-like alkylating agents, but it also extends to other drugs such as cyclophosphamide. This has been demonstrated in diffuse large cell lymphomas treated with cyclophosphamide, where MGMT hypermethylation was the strongest predictor of overall survival and time to progression, and was far superior to classical clinical factors such as the International Prognostic Index. Finally, others and we have extended in gliomas the use of MGMT-methylation as a marker of good clinical response for another drug recently introduced, temozolomide.
Black American Health
Authors: Linnea Capps
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Relationship between ciprofloxacin resistance and extended-spectrum β-lactamase production in Escherichia coli and Klebsiella pneumoniae strains
Authors: V. Tolun, Ö. Küçükbasmaci, D. Törümküney-Akbulut, Ç. Çatal, M. Anğ-Küçüker, Ö. Auğ
Journal: Clinical Microbiology and Infection (2004)
Abstract 1357: Renal Dysfunction, Fitness and the Risk of Death in Women
Authors: Martha Gulati, Henry R Black, Morton Arnsdorf, Roxanne Wicklund, Arfan J Al-Hani, George Bakris
Journal: Circulation (2009)

Background: Chronic kidney disease is associated with increased risk of cardiovascular (CV) events and death, but its association with cardiorespiratory fitness is unknown in women. Methods: To ass...
Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review How does herd immunity work?
Authors: T. Panagiotopoulos, I. Antoniadou, E. Valassi-Adam, A. Berger
Journal: BMJ (1999)

To describe the events leading to the epidemic of congenital rubella syndrome in Greece in 1993 after a major rubella epidemic.Retrospective survey and systematic review.Greece (population 10 million), 1950-95.Children, adolescents, and women of childbearing age.Around 1975 in Greece the measles, mumps, and rubella vaccine started being given to boys and girls aged 1 year without policies to attain high vaccination coverage and to protect adolescents and young women. During the 1980s, vaccination coverage for rubella remained consistently below 50%, and the proportion of pregnant women susceptible to rubella gradually increased. In 1993 the incidence of rubella in young adults was higher than in any previous epidemic year. The epidemic of congenital rubella that followed, with 25 serologically confirmed cases (24.6 per 100 000 live births), was probably the largest such epidemic in Greece after 1950.With low vaccination coverage, the immunisation of boys and girls aged 1 year against rubella carries the theoretical risk of increasing the occurrence of congenital rubella. This phenomenon, which has not been previously reported, occurred in Greece.
Abstract 2965: Cardiomyocyte Sheets Derived From Induced Pluripotent Stem (iPS) Cells Improve Cardiac Function and Attenuate Cardiac Remodeling in Myocardial Infarction in Mice
Authors: Kenji Miki, Atsuhiro Saito, Hisazumi Uenaka, Shigeru Miyagawa, Tatsuya Shimizu, Teruo Okano, Shinya Yamanaka, Yoshiki Sawa
Journal: Circulation (2009)

Cell transplantation derived from autologous cells after myocardial infarction is a promising strategy. ES cells represent an attractive candidate cell source for obtaining cardiomyocytes and other...
Cardiovascular comorbidities of COPD in never-smokers
Authors: Stig Hagstad, Helena Backman, Anne Lindberg, Eva Rönmark, Bo Lundbäck, Anders Bjerg
Journal: European Respiratory Journal (2014)

Background : Cardiovascular comorbidities are common in COPD. Smoking is a major determinant of both COPD and cardiovascular disease. The prevalence of comorbidities among never-smokers with COPD is largely unknown.   Aim : To study the prevalence of cardiovascular comorbidities in never-smokers with COPD.   Methods : Pooled data from three cross-sectional surveys of the Obstructive Lung Disease in Northern Sweden (OLIN) Study was used. 3963 subjects with valid spirometric data were included, of them 1609 were never-smokers. COPD was defined according to GOLD using post-bronchodilator spirometry.   Results : 681 (17.2%) of all subjects had COPD, 361 (9.1%) had GOLD stage ≥2. Among never-smokers the corresponding figures were 150 (9.3%) and 71 (4.4%). Adjusted for sex and age, GOLD stage ≥2 in never-smokers was associated with having any cardiovascular disease, OR 1.90 (1.12-3.24). In never-smokers with no COPD, GOLD stage 1 and stage ≥2 respectively, any cardiac disease was seen in 20.2%, 20.3% and 32.4% (p=0.028) compared to 22.4%, 25.2% and 33.8% (pl0.001) in the corresponding groups of ever-smokers. Prevalence of hypertension in never-smokers in the respective groups was 33.4%, 48.1% and 53.5% (pl0.001) compared to 33.2%, 32.8% and 44.4% (p=0.001) in ever-smokers. Similar patterns were seen for anti-hypertensive and cardiac medications in never- and ever-smokers with COPD.   Conclusions : In never-smokers COPD GOLD stage ≥2 was associated with cardiovascular comorbidities independently of sex and age. The prevalence of cardiovascular comorbidities by GOLD stage was similar in never- and ever-smoking subjects. Physicians treating COPD patients should consider cardiovascular comorbidities also in subjects with no smoking history.
Emergency response to 999 calls
Authors: B. A Foex
Journal: BMJ (2002)

Emergency response to 999 calls Alternatives to the emergency 999 response can be seen in EuropeEditor-Snooks et al point out that the current 999 emergency response system has problems: increasing demand from the public and ever shorter response time targets. 1 They find a lack of evidence on alternative systems and responses in the English medical literature.By restricting their search, they overlook live examples only a few miles from these shores.France, since the mid-1960s, has had a system which incorporates many of the alternatives quoted by the authors: the Service d'Aide Medical Urgente (SAMU). 2 Calls to the control room are logged by trained telephone operators and then passed on to a "medical dispatcher": a doctor in emergency medicine, trained by the service.Medical dispatchers may simply provide medical advice to the caller, or they may decide to use one of a range of other responses to a call.These are referral to, or the dispatch of, a primary care doctor; arranging nonurgent transport by a private ambulance; urgent transport by pompiers (emergency technicians working through the fire service); or sending out a mobile intensive care unit with a doctor trained in emergency medicine.Medical dispatchers also coordinate the deployment of additional resources and decide on the most appropriate destination for a patient.In 2001 the service covering Paris received 300 000 calls (about 820 calls per day).Only 6% of the calls (50 per day) resulted in the dispatch of a mobile intensive care unit.In 16% of cases (130 per day) a primary care doctor was called.Altogether 205 calls per day were managed by the pompiers, by a private ambulance, or by giving medical advice.The remainder were
Abstract 4229: ATP-binding cassette transporter ABCG2/BCRP inhibition sensitizes CD133+ cells to MEK/BRAF inhibitors
Authors: Abrar Mohamad Pauzi
Journal: Cancer Research (2015)

Abstract Melanoma is a highly aggressive type of skin cancer. Melanoma-initiating cells (MIC) have self-renewal capacity, are highly tumorigenic and have been identified using CD133, a cell surface marker consisting of a 5-transmembrane protein. After magnetic sorting with anti-CD133 beads, we determined that CD133+ populations were more resistant than CD133- cells to MEK/BRAF inhibitors, the latter of which are targeted therapies for melanoma currently in clinical trials. In a microarray study, we found that the ABCG2 transporter is upregulated in the CD133+ MIC subpopulations. ABCG2, also known as breast cancer resistant protein (BCRP), is an ATP-binding cassette (ABC) transporter that facilitates the efflux of xenobiotics at the plasma membrane and is responsible for multidrug resistance in cancer cells. This study therefore aimed to block the ABCG2 transporter using the dual ABCG2/ABCB1 inhibitor elacridar to sensitize the CD133+ subpopulation to MEK/BRAF inhibitors. Three metastatic primary human melanoma cell lines were used to investigate the effects of inhibiting ABCG2 in drug-resistant CD133+ subpopulations. Elacridar was used for in vitro inhibition of ABCG2 prior to addition of single and combination treatments with trametinib (a MEK inhibitor), dabrafenib (a BRAF inhibitor), and mebendazole (an anthelmintic and possibly anticarcinogenic drug). Elacridar sensitized all treatment groups to drug treatment. Combination treatment using both ABCG2 and MEK/BRAF inhibitors at the lowest effective dose could be a potential therapeutic to eliminate the highly aggressive drug-resistant CD133+ MIC subpopulations. Citation Format: Abrar Mohamad Pauzi. ATP-binding cassette transporter ABCG2/BCRP inhibition sensitizes CD133+ cells to MEK/BRAF inhibitors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4229. doi:10.1158/1538-7445.AM2015-4229
Chemotherapy—A Viable Partner for Cancer Immunotherapy?
Authors: Leisha A. Emens
Journal: JAMA Oncology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The effect of locally applied TGF-BETA3 on wound healing and stenosis development in tracheal surgery
Authors: Aykut Eliçora, Serife Tuba Liman, Betül Arica Yegin, Asli Gül Akgül, Hakan Eroglu, Kürsat Yildiz, Salih Topçu, Cüneyt Özer
Journal: European Respiratory Journal (2012)

INTRODUCTION: Tracheal stenosis constitutes one of the most frequently seen problems in thoracic surgery. Although many treatment modalities to prevent tracheal stenosis have been attempted, an effective method has not been found yet. In this study, TGF-beta3/chitosan combination was used for that purpose.

MATERIAL-METHOD: A film shaped slow releasing preparation, which contains TGF-beta3 with basal substance of chitosan was created. Thirty ''Wistar Albino'' rats were divided into 3 groups. Full layer vertical incision was made in the anterior side of trachea between 2. and 5. tracheal rings. Membranous trachea was preserved. Tracheal incision was sutured. Group A was evaluated as control group. In group B, a chitosan based film substance was placed on the incision line. In group C, a chitosan- TGF- β3 combination slow-release film coated substance was placed on the incision line. The rats were sacrificed on 30th day, the tracheas of the rats were excised by cutting between the lower edge of the thyroid cartilage and the upper edge of the 6th tracheal ring together with oesophagus. Epithelialization, fibroblast proliferation, angiogenesis, inflammation and collagen levels were evaluated histopathologically by the same histopathologist (Figure).

RESULTS: It was not found statistically significant difference between three groups. Cold abscesses were observed at the incision area in both TGFB3/chitosan combination and chitosan groups and they were thought to form because of chitosan.
Abstract 17348: Necrostatin 7 Limits Myocardial Infarct Size and Reduces Cardiac Remodeling After Permanent Coronary Occlusion in Rats
Authors: Yuri Dmitriev, Sarkis Minasian, Anna Dracheva, Andrey Karpov, Svetlana Chefu, Elena Demchenko, Michael Galagudza
Journal: Circulation (2014)

Background: Reduction of irreversible myocardial ischemia-reperfusion injury (IRI) remains important. One of the promising strategies aimed at myocardial IRI alleviation is modulation of programmed cell death (PCD) pathways. PCD mode displaying morphological characteristics of necrosis, and amenable to pharmacological manipulation is referred to as necroptosis. Necroptosis inhibitor necrostatin-1 has been shown to exert cardio- and neuroprotective effects. In the present work, the effect of necrostatin-7 (Nec-7) on myocardial injury in the rat model of permanent coronary occlusion was studied. Methods: Male Wistar rats (n = 19) were anesthetized with pentobarbital. The animals were subjected to permanent coronary occlusion (PCO) and intraperitoneal (i.p.) Nec-7 administration 1 h prior to PCO at a dose of 14.5 mg/kg in dimethyl sulfoxide (DMSO) or DMSO alone at a dose of 3.1 g/kg. Control rats were treated with saline. Three weeks after PCO, serum levels of NT-proBNP were measured, and histological outcomes were assessed. The infarct size (IS, %) and infarct length (IL, mm) were analyzed morphometrically. Results: DMSO caused significant reduction in serum NT-proBNP level vs. Control (0.3 ± 0.19 vs. 0.5 ± 0.22 ng/ml, p = 0.001), while Nec-7 further decreased NT-proBNP level in comparison with DMSO (0.2 ± 0.14 ng/ml, p = 0.008 vs. DMSO). Compared with Control, DMSO reduced adverse left ventricular remodeling, as evidenced by reduction in IS (16.0 ± 2.92 and 12.9 ± 1.72%, p = 0.015) and IL (6.2 ± 0.89 and 3.8 ± 0.35 mm, p = 0.008). Nec-7 treatment resulted in additional reduction of both IS and IL vs. DMSO group (9.0 ± 4.91 % and 2.9 ± 1.62 mm, respectively; p = 0.013 and p = 0.011 vs. DMSO, respectively). Conclusion: Nec-7 has cardioprotective properties, reducing myocardial wall stress and myocardial remodeling in the rat model of myocardial infarction.